Takeda Pharmaceutical Co Ltd

Takeda’s CNS strategy—selling TAK‑063 to Axsome while pushing Oveporexton toward approval—demonstrates how the company balances monetization, risk, and growth in neurological therapeutics.

Takeda’s new oral TYK2 inhibitor zasocitinib shows rapid, sustained clearance in moderate‑to‑severe psoriasis, offering a once‑daily option that could reshape care and deliver high‑margin revenue while easing payer concerns with its favorable safety…

Takeda’s recent Form 3 filings reveal unchanged executive shareholdings and consistent vesting schedules, underscoring its commitment to transparent governance and stable investor confidence.

Takeda’s Phase 3 KEPLER trial shows vedolizumab (ENTYVIO®) achieves 32 % remission and 36 % mucosal healing in children with ulcerative colitis, confirming safety and paving the way for pediatric approval.

Takeda launches low‑IgA, ready‑to‑use GAMMAGARD LIQUID ERC in the U.S. to streamline PI therapy, cut admin costs, and outpace competitors with a strong IP moat.

Takeda Pharmaceutical’s 2026 analyst outlook: a Hold rating amid steady growth, solid capital, and a diversified oncology‑CNS portfolio that keeps investors watching Japan’s pharma scene.

Takeda’s strong oncology pipeline and AI‑powered drug‑development tools are boosting analyst confidence and positioning the company for growth in Japan and global markets.

Takeda’s Phase 3 win for oral psoriasis drug zasocitinib offers a safe, effective, cost‑efficient option poised to reshape the competitive, reimbursement‑driven dermatology market.

Takeda’s 52‑week VERIFY study shows rusfertide safely reduces phlebotomy in polycythemia vera, offering durable efficacy and a strong commercial case for market access.

Takeda’s 52‑week rusfertide study shows 83 % hematocrit control and low thrombotic risk, while its multibillion‑dollar Innovent partnership targets next‑gen immuno‑oncology therapies.